Rigorous T cell depletion methods can now be used to reduce the risk of graft-versus-host disease (GVHD) associated with allogeneic, hematopoietic stem cell transplantation (HSCT). However, full T cell depletion is also associated with a significant risk of graft failure. Here we hypothesize that engraftment failures after T cell-depleted HSCT may be due, in part, to the absence of GVHD prophylaxis. To test this hypothesis, we used a haploidentical mouse model to systematically measure the effects of immunosuppressive drug treatments and anti-T cell antibodies on engraftment. Results showed that engraftment was supported in all animals when hosts were pre-treated with anti-T cell antibodies, but donor chimerism was significantly improved when hosts were also treated with prednisone. Interestingly, when hosts received only pre-HSCT prednisone treatments, engraftment was not improved; when hosts received only post-HSCT prednisone (initiated near the time of irradiation), the animals became extremely ill. Results therefore demonstrated the need for both pre-and post-HSCT prednisone treatments as a means to ensure engraftment without morbidity in all host animals.
antibodies. 10 For example, in a recent report there were three failed or rejected grafts among nine patients with CML, AML or ALL who received megadoses of T celldepleted haploidentical stem cells. One patient also failed to engraft after a second infusion of stem cells. 2 In two larger series, 11, 12 engraftment failures were observed in 5/23 and 2/43 patients, respectively. Clearly, the advantages of T cell depletion can not be realized in the absence of engraftment. The use of large numbers of stem cells is encouraged to avoid graft failure, [3] [4] [5] 13, 14 but the size of the stem cell dose is ultimately limited by the inherent constraints of stem cell harvest and purification.
Here, we hypothesize that the omission of GVHD prophylaxis in the context of T cell-depleted, haploidentical, hematopoietic stem cell transplantation (HSCT) hampers engraftment, even when hosts are pre-treated with anti-T cell antibodies. We predict that the treatment of recipients with immunosuppressive drugs in combination with anti-T cell antibodies may improve outcome.
The evaluation of risks and benefits attributed to immunosuppressive drug usage is difficult in human HSCT due to the complexities of treatment and the high variability among transplant centers regarding the purpose and schedules of drug dosing. In some centers, immunosuppressive drugs are prescribed expressly to enhance engraftment, while in other centers, drugs are prescribed to prevent/treat GVHD or antibody-induced hypersensitivity. 6, 9, [15] [16] [17] To simplify the study of HSCT regimens, we therefore chose to employ a mouse model for haploidentical HSCT. ) animals from Jackson Laboratories (Bar Harbor, ME, USA) served as donors and hosts, respectively. On the day of HSCT (day 0), host mice were irradiated with a single dose of 850 cGy and were then injected intravenously with 10 7 T celldepleted bone marrow cells in phosphate buffered saline (PBS). The T cell depletion of bone marrow cells was performed by washing and suspending cells (10 8 ) in 2 ml of cold serum-free RPMI containing 1:100 dilutions of three ascites preparations (Jij (anti-Thy 1.2), 3.1688 (anti-CD8) and RL172.4 (anti-CD4)) 18 for 30 min on ice. Washed cells were then incubated for 1 h at 37°C in 1.25 ml of complement (1:5 dilution low-tox guinea pig complement and 1:25 dilution low-tox rabbit complement (CedarLane, Ontario, Canada) in RPMI). Cells were washed extensively before infusion.
Materials and methods

Mouse model
Host treatments
The mouse model was designed to define the potential effects of combination treatments, rather than to define precise clinical HSCT regimens. Therefore, drug doses that were well tolerated when individually administered to healthy host animals were selected. Doses were: 15/mg/kg/day prednisone (Roxane, Oral solution, USP, oral gavage), 50 mg/kg/day CsA (Novartis, Sandimmune oral solution, oral gavage) and/or 0.5 ml anti-T cell antibodies (mixed anti-CD8 (2.43 ascites, 1:10 dilution, ATCC, Rockville, MD, USA) and anti-CD4 (GK1.5 ascites, 1:5 dilution, ATCC) antibody, intraperitoneal injection).
Analysis of donor chimerism
Donor chimerism was examined 3 weeks post HSCT as described previously, 10 with minor modifications. Briefly, blood was collected in heparin and red blood cells were lysed with ammonium chloride. Cells were washed, resuspended in PBS containing 10% normal mouse serum and 2. In preliminary experiments, blood granulocytes were also monitored. These experiments showed that groups of animals with high levels of donor chimerism among PBL, also had high levels of donor chimerism among granulocytes.
Results and discussion
Here, we describe a mouse model system used to define variables supportive of T cell-depleted haploidentical, stem cell engraftment. All mice were irradiated with a single dose of 850 cGy and immediately administered 10 7 bone marrow cells, thoroughly depleted of T cells by antibody and complement treatments. In the absence of additional conditioning, mice showed no engraftment, suggesting that host T cell compartments were intact, and were actively rejecting donor stem cells (Table 1A) .
To define parameters supportive of engraftment, hosts were treated with immunosuppressive drugs, with or without anti-T cell antibodies, in addition to irradiation. As shown in a representative experiment in Table 1A , the treatment of host mice with cyclosporine A (CsA) alone (for 20 days, days Ϫ10 to Ϫ1 and days 1 to 10) did not enhance engraftment. This result was consistent with previous demonstrations that CsA is effective only if administered for a very long period post HSCT, 19, 20 a regimen that prolongs immunodeficiency and host susceptibility to infectious disease.
The acute administration of prednisone alone (for 20 days, days Ϫ10 to Ϫ1 and days 1 to 10), or in combination with CsA, supported engraftment in some but not all mice, while antibody treatments (days Ϫ2 and Ϫ4) yielded moderate engraftment in every animal tested (Table 1A) . Engraftment was most pronounced when prednisone (administered for 20 days, 10 days pre-and 10 days post HSCT) was added to antibody treatments (administered on days Ϫ2 and Ϫ4). This was significantly better than treatments with antibody alone (Mann-Whitney test, P Ͻ 0.05). Engraftment was durable, in that after 10 to 12 months, all mice that received prednisone plus antibody maintained 87% to 100% donor chimerism. In contrast, mice that exhibited poor donor chimerism at early stages, frequently maintained poor donor chimerism, or suffered complete graft rejection (data not shown).
The addition of CsA to combined antibody and prednisone treatments did not improve outcome (Table 1A) . Treatments with CsA and antibody also yielded no improved engraftment beyond that achieved with antibody alone (data not shown).
We next questioned whether the synergy demonstrated between prednisone and antibody could also be achieved if prednisone was administered for only 10 days pre-HSCT (days Ϫ10 to Ϫ1). As shown in Table 1B , it could not: the 10-day pre-treatment with prednisone and/or CsA did not improve the engraftment achieved with antibody alone.
Next, we tested whether synergy would be observed if prednisone was administered for only 10 days post HSCT (days 1 to 10). Surprisingly, we found that mice treated in this way suffered significant morbidity (lethargy, ruffled hair, wasting) and mortality, even though their course of treatment was shorter than treatments described above (see Table 1C for representative data). When antibody was removed from the regimen (Table 1D) , the morbidity/ mortality was not alleviated. Apparently, the initiation of prednisone treatments was associated with toxin-release from a large number of damaged cells, which were ultimately cleared from the system. This shock overwhelmed the host when prednisone-induced cell damage was coincident with irradiation-induced cell damage. The situation was avoided when we pre-adapted mice to prednisone by initiating prednisone treatments well in advance of irradiation. Results in Table 1C and D help to explain the profound treatment-related toxicities observed in a recent clinical study, in which prednisone was initiated on day ϩ1 post HSCT. 21 It might be argued that the mouse morbidity was a consequence of GVHD. However, we think this explanation is unlikely, because stem cells were thoroughly T celldepleted and there was no morbidity in HSCT recipients given no prednisone, or animals given prednisone both preand post HSCT (histology was not performed). The restricted appearance of morbidity in the post-HSCT prednisone treatment group suggested that combination drug/ irradiation toxicities were the cause. Might morbidity have been reduced in our experiments had the post-HSCT prednisone dose been lowered? Most likely, a reduction in the post-HSCT prednisone dose would have lessened the combined drug/irradiation toxicity. It should be noted, however, that the initiation of 1-2 mg/kg prednisone treatments on day ϩ1 following clinical BMT has been associated with dramatic procedure-related mortalities. 21 Thus, even if post-HSCT prednisone treatments of 1-2 mg/kg could be used to improve engraftment, such treatments should not be implemented without a course of pre-HSCT drug adaptation.
Overall, the best outcome among test mice was achieved when we combined anti-T cell antibodies with both preand post-HSCT prednisone treatments. Because these acute, combination treatments supported engraftment, treatments with long-term post-HSCT immunosuppressants (and longterm immunodeficiency 19, 20 ) could be avoided. The synergy observed in our experiments probably reflected the disparate mechanisms of antibody and prednisone functions. While anti-T cell antibodies depend upon T cell membrane markers for cell targeting, prednisone (a synthetic analogue of cortisol) is able to penetrate, alter, and lyse lymphocytes even when marker expression is low or absent. These Donor chimerism was measured 3 weeks post HSCT after various host treatments with anti-T cell antibody, CsA, prednisone, or combinations of the three. The anti-T cell antibodies were delivered on days Ϫ2 and Ϫ4. CsA and prednisone treatments were pre-HSCT (days Ϫ10 to Ϫ1), post HSCT (days 1 to 10) or pre-and post HSCT (days Ϫ1 to Ϫ10 and days 1 to 10). Asterisks identify treatment groups in which engraftment was significantly improved compared to the group treated with anti-T cell antibodies alone. 
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Mice were treated with prednisone plus or minus antibody. Morbidity (lethargy, ruffled hair, wasting)/mortality was observed in most prednisone-treated mice.
inherent functional differences highlight the potential usefulness of prednisone and anti-T cell antibodies in combination therapy.
In conclusion, experiments in the mouse model have allowed us to dissect the role of antibody and drug treatments administered pre-and post HSCT. In this model, anti-T cell antibody was shown to support the engraftment of HSCT at moderate levels (as previously described 10, 22 ), but engraftment was greatly improved when high-dose prednisone (administered for 10 days pre-HSCT and 10 days post HSCT) was added to the regimen. These results clearly cannot be translated directly to clinical application, but they may be used to formulate hypotheses relevant to human studies. We propose that the acute administration of high-dose prednisone (regardless of the need for prophylaxis against GVHD or antibody-induced hypersensitivity 17 ), in combination with anti-T cell antibodies, may improve the engraftment of haploidentical, T cell-depleted stem cells in the clinical setting. We suggest that post-HSCT prednisone may be warranted to ensure engraftment, while pre-HSCT prednisone may be warranted to temporally separate the toxic effects of drug-mediated and radiation-mediated cell damage. Caution should be taken to avoid the initiation of prednisone near the time of irradiation, as this has been associated with serious illness, both in the present study and in recent clinical trials. 21 
